- Correction
- Open access
- Published:
Correction: Novel fusion protein PK5-RL-Gal-3 C inhibits hepatocellular carcinoma via anti-angiogenesis and cytotoxicity
BMC Cancer volume 23, Article number: 359 (2023)
The Original Article was published on 15 February 2023
Correction: BMC Cancer 23, 154 (2023)
Following publication of the original article [1], the authors identified an error in Fig. 3F. The representative tube formation figure of lactose group was wrong. The correction does not have any effect on the results and conclusions of the article. The corrected Fig. 3 is given in this correction article and the original article [1] is corrected.
PK5-RL-Gal-3 C inhibits angiogenesis in vivo and in vitro. Tube formation assay in vitro was performed to determine the inhibitory effect of rPK5-RL-Gal-3 C on angiogenesis according to the materials and methods. A and B rPK5-RL-Gal-3 C exhibited stronger inhibitory action than E25, rPK5 and rGal-3 C on tube formation in vitro. After treated with H1/EEV and H1/EEV-PK5-RL-Gal-3 C nanoparticles, the tumors were removed and stained by CD31 antibody using IHC. C and D H1/EEV-PK5-RL-Gal-3 C treatment down-regulated the expression of CD31 in tumor tissues. VEGF-induced matrigel plug assay in vivo were performed to determine the inhibitory effect of rPK5-RL-Gal-3 C on angiogenesis according to the materials and methods. E rPK5-RL-Gal-3 C exhibited stronger inhibitory action than rPK5 and rGal-3 C in VEGF-induced matrigel plug assay model in vivo. F and G lactose partially blockaded the inhibitory action of rPK5-RL-Gal-3 C but not sucrose. Significant differences are denoted by * for p < 0.05, ** for p < 0.01, *** for p < 0.001 and ns, no significance
References
Gao X, Jiang P, Wei X, et al. Novel fusion protein PK5-RL-Gal-3 C inhibits hepatocellular carcinoma via anti-angiogenesis and cytotoxicity. BMC Cancer. 2023;23:154. https://doi.org/10.1186/s12885-023-10608-9.
Author information
Authors and Affiliations
Corresponding authors
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The online version of the original article can be found at https://doi.org/10.1186/s12885-023-10608-9.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Gao, X., Jiang, P., Wei, X. et al. Correction: Novel fusion protein PK5-RL-Gal-3 C inhibits hepatocellular carcinoma via anti-angiogenesis and cytotoxicity. BMC Cancer 23, 359 (2023). https://doi.org/10.1186/s12885-023-10843-0
Published:
DOI: https://doi.org/10.1186/s12885-023-10843-0